IPO - RECURSION PHARMACEUTICALS, INC.

Form Type: S-3ASR

Filing Date: 2025-02-12

Corporate Action: Ipo

Type: New

Accession Number: 000119312525025185

Filing Summary: Recursion Pharmaceuticals, Inc. filed an S-3ASR registration statement with the SEC on February 12, 2025, allowing for the issuance of various securities, including Class A Common Stock, preferred stock, debt securities, and more. The document indicates that securities may be offered periodically after the effective date of the registration statement as part of a shelf registration process. This includes potential offerings by selling stockholders, which will be detailed in prospectus supplements. The company emphasizes its focus on biologically-driven drug discovery, leveraging a proprietary data set. The recent acquisition of Exscientia in November 2024 is noted, enhancing their drug discovery capabilities. The document contains essential information regarding risks, forward-looking statements, and the intended use of proceeds from the offerings, which may include working capital and acquiring complementary technologies.

Document Link: View Document